frozen snapshot — 2026-08-05 · see today →

What's on Reshma Kewalramani's mind?

read fresh this morning at 6

29%23%19%10%19%

Q2 results and raised 2026 guidance 29% The $10B Crinetics acquisition 23% IgA nephropathy FDA verdict 19% Life after the CF franchise 10% everything else 19%

Vertex posts a strong Q2 and raises the 2026 revenue bar

The quarter landed well enough that she moved the full-year number up rather than sitting on the beat.

Vertex raises 2026 revenue guidance as CEO touts benefits of $10 billion Crinetics deal

The Business Journals · 2026-08-04

our translation

raising guidance in august is a confidence signal you can't walk back quietly. she'd rather set a higher bar in public than let anyone price vertex as a one-drug company coasting on trikafta.

Q2 print carried by multiple outletsvery sure · 2 sources

CEO spends earnings day defending the $10 billion Crinetics logic

CEO touted deal on earnings dayvery sure · 1 source

Vertex says it's unfazed as an IgAN decision looms in a crowded field

FDA verdict approaching, competitors crowdingpretty sure · 1 source

Every headline she wants is about a drug that isn't for cystic fibrosis

Diversification framing anchors earnings coveragepretty sure · 1 source

wednesday, august 5

Take the raised-guidance victory lap with sell-side analysts(safe bet)

Re-check IgAN launch readiness before the FDA date lands(reported)

Pressure-test Crinetics integration milestones against the $10B math(safe bet)

Ask how much of the Q2 upside came from outside CF(safe bet)

rebuilt from the public schedule, pool reports & old habits — the rest is educated guessing

The source

Vertex raises 2026 revenue guidance as CEO touts benefits of $10 billion Crinetics deal

news.google.com · 2026-08-05

every line on the pad traces to something public — tap to see it